|
1
|
Liu L, Wu X, Liu L, Geng J, Yuan Z, Shan Z
and Chen L: Prevalence of diabetic retinopathy in mainland China: A
meta-analysis. PLoS One. 7(e45264)2012.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Kumar K, Baliga G, Babu N, Rajan RP, Kumar
G, Mishra C, Chitra R and Ramasamy K: Clinical features and
surgical outcomes of complications of proliferative diabetic
retinopathy in young adults with type 1 diabetes mellitus versus
type 2 diabetes mellitus-A comparative observational study. Indian
J Ophthalmol. 69:3289–3295. 2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Stewart MW, Browning DJ and Landers MB:
Current management of diabetic tractional retinal detachments.
Indian J Ophthalmol. 66:1751–1762. 2018.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Hershberger VS, Augsburger JJ, Hutchins
RK, Raymond LA and Krug S: Fibrovascular ingrowth at sclerotomy
sites in vitrectomized diabetic eyes with recurrent vitreous
hemorrhage: Ultrasound biomicroscopy findings. Ophthalmology.
111:1215–1221. 2004.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Ahn J, Woo SJ, Chung H and Park KH: The
effect of adjunctive intravitreal bevacizumab for preventing
postvitrectomy hemorrhage in proliferative diabetic retinopathy.
Ophthalmology. 118:2218–2226. 2011.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Fujii GY, De Juan E Jr, Humayun MS, Chang
TS, Pieramici DJ, Barnes A and Kent D: Initial experience using the
transconjunctival sutureless vitrectomy system for vitreoretinal
surgery. Ophthalmology. 109:1814–1820. 2002.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Oshima Y, Wakabayashi T, Sato T, Ohji M
and Tano Y: A 27-gauge instrument system for transconjunctival
sutureless microincision vitrectomy surgery. Ophthalmology.
117:93–102.e2. 2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Shahzadi B, Rizwi SF, Qureshi FM, Latif K
and Mahmood SA: Outcomes of transconjunctival sutureless 27-gauge
micro-incision vitrectomy surgery in diabetic vitreous haemorrhage.
Pak J Med Sci. 33:86–89. 2017.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Khan MA, Shahlaee A, Toussaint B, Hsu J,
Sivalingam A, Dugel PU, Lakhanpal RR, Riemann CD, Berrocal MH,
Regillo CD and Ho AC: Outcomes of 27 gauge microincision vitrectomy
surgery for posterior segment disease. Am J Ophthalmol.
161:36–43.e1-e2. 2016.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Ribeiro L, Oliveira J, Kuroiwa D, Kolko M,
Fernandes R, Junior O, Moraes N, Vasconcelos H, Oliveira T and Maia
M: Advances in vitreoretinal surgery. J Clin Med.
11(6428)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Dugel PU, Abulon DJ and Dimalanta R:
Comparison of attraction capabilities associated with high-speed,
dual-pneumatic vitrectomy probes. Retina. 35:915–920.
2015.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Dugel PU, Zhou J, Abulon DJK and Buboltz
DC: Tissue attraction associated with 20-gauge, 23-gauge, and
enhanced 25-gauge dual-pneumatic vitrectomy probes. Retina.
32:1761–1766. 2012.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Semeraro F, Cancarini A, dell'Omo R,
Rezzola S, Romano MR and Costagliola C: Diabetic retinopathy:
Vascular and inflammatory disease. J Diabetes Res.
2015(582060)2015.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Qaum T, Xu Q, Joussen AM, Clemens MW, Qin
W, Miyamoto K, Hassessian H, Wiegand SJ, Rudge J, Yancopoulos GD
and Adamis AP: VEGF-initiated blood-retinal barrier breakdown in
early diabetes. Invest Ophthalmol Vis Sci. 42:2408–2413.
2001.PubMed/NCBI
|
|
15
|
Funatsu H, Yamashita H, Ikeda T, Mimura T,
Eguchi S and Hori S: Vitreous levels of interleukin-6 and vascular
endothelial growth factor are related to diabetic macular edema.
Ophthalmology. 110:1690–1696. 2003.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Kohno R, Hata Y, Mochizuki Y, Arita R,
Kawahara S, Kita T, Miyazaki M, Hisatomi T, Ikeda Y, Aiello LP and
Ishibashi T: Histopathology of neovascular tissue from eyes with
proliferative diabetic retinopathy after intravitreal bevacizumab
injection. Am J Ophthalmol. 150:223–229.e1. 2010.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Wang DY, Zhao XY, Zhang WF, Meng LH and
Chen YX: Perioperative anti-vascular endothelial growth factor
agents treatment in patients undergoing vitrectomy for complicated
proliferative diabetic retinopathy: A network meta-analysis. Sci
Rep. 10(18880)2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Simunovic MP and Maberley DA:
Anti-vascular endothelial growth factor therapy for proliferative
diabetic retinopathy: A systematic review and meta-analysis.
Retina. 35:1931–1942. 2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Zhang M, Zhang J, Yan M, Luo D, Zhu W,
Kaiser PK and Yu DC: KH902 Phase 1 Study Group. A phase 1 study of
KH902, a vascular endothelial growth factor receptor decoy, for
exudative age-related macular degeneration. Ophthalmology.
118:672–678. 2011.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Yang X, Xu J, Wang R, Mei Y, Lei H, Liu J,
Zhang T and Zhao H: A randomized controlled trial of conbercept
pretreatment before vitrectomy in proliferative diabetic
retinopathy. J Ophthalmol. 2016(2473234)2016.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Mao JB, Wu HF, Chen YQ, Zhao SX, Tao JW,
Zhang Y, Zheng B, Wang L and Shen LJ: Effect of intravitreal
conbercept treatment before vitrectomy in proliferative diabetic
retinopathy. Int J Ophthalmol. 11:1217–1221. 2018.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Kitagawa Y, Shimada H, Yukita M and Naruse
S: Silicone oil injection and removal in 27-gauge vitreous surgery.
Int J Ophthalmol. 16:139–142. 2023.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Nam Y, Chung H, Lee JY, Kim JG and Yoon
YH: Comparison of 25- and 23-gauge sutureless microincision
vitrectomy surgery in the treatment of various vitreoretinal
diseases. Eye (Lond). 24:869–874. 2010.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Osawa S and Oshima Y: 27-Gauge vitrectomy.
Dev Ophthalmol. 54:54–62. 2014.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Gupta V and Arevalo JF: Surgical
management of diabetic retinopathy. Middle East Afr J Ophthalmol.
20:283–292. 2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Mitsui K, Kogo J, Takeda H, Shiono A,
Sasaki H, Munemasa Y, Kitaoka Y and Takagi H: Comparative study of
27-gauge vs 25-gauge vitrectomy for epiretinal membrane. Eye
(Lond). 30:538–544. 2016.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kunikata H, Yasuda M, Aizawa N, Osada U,
Nishiguchi KM, Abe T and Nakazawa T: Retinal sensitivity and vessel
density after macular hole surgery with the superior inverted
internal limiting membrane flap technique. Retina. 41:45–53.
2021.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Chen PL, Chen YT and Chen SN: Comparison
of 27-gauge and 25-gauge vitrectomy in the management of tractional
retinal detachment secondary to proliferative diabetic retinopathy.
PLoS One. 16(e0249139)2021.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Naruse Z, Shimada H and Mori R: Surgical
outcomes of 27-gauge and 25-gauge vitrectomy day surgery for
proliferative diabetic retinopathy. Int Ophthalmol. 39:1973–1980.
2019.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Rizzo S, Barca F, Caporossi T and Mariotti
C: Twenty-seven-gauge vitrectomy for various vitreoretinal
diseases. Retina. 35:1273–1278. 2015.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Romano MR and Cennamo G, Ferrara M,
Cennamo M and Cennamo G: Twenty-seven-gauge versus 25-gauge
vitrectomy for primary rhegmatogenous retinal detachment. Retina.
37:637–642. 2017.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Rizzo S, Polizzi S, Barca F, Caporossi T
and Virgili G: Comparative study of 27-gauge versus 25-gauge
vitrectomy for the treatment of primary rhegmatogenous retinal
detachment. J Ophthalmol. 2017(6384985)2017.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kasi SK, Hariprasad SM and Hsu J: Making
the jump to 27-gauge vitrectomy: Perspectives. Ophthalmic Surg
Lasers Imaging Retina. 48:450–456. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Issa SA, Connor A, Habib M and Steel DH:
Comparison of retinal breaks observed during 23 gauge
transconjunctival vitrectomy versus conventional 20 gauge surgery
for proliferative diabetic retinopathy. Clin Ophthalmol. 5:109–114.
2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Zhang ZH, Liu HY, Hernandez-Da Mota SE,
Romano MR, Falavarjani KG, Ahmadieh H, Xu X and Liu K: Vitrectomy
with or without preoperative intravitreal bevacizumab for
proliferative diabetic retinopathy: A meta-analysis of randomized
controlled trials. Am J Ophthalmol. 156:106–115.e2. 2013.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Abulon DJK and Buboltz DC: Performance
comparison of high-speed dual-pneumatic vitrectomy cutters during
simulated vitrectomy with balanced salt solution. Transl Vis Sci
Technol. 4(6)2015.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Abulon DJ: Vitreous flow rates through
dual pneumatic cutters: Effects of duty cycle and cut rate. Clin
Ophthalmol. 9:253–261. 2015.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Steel DH and Charles S: Vitrectomy
fluidics. Ophthalmologica. 226 (Suppl 1):S27–S35. 2011.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Dave VP, Pathengay A, Basu S, Gupta N,
Basu S, Raval V, Das T, Sharma S, Mathai A, Narayanan R, et al:
Endophthalmitis after pars plana vitrectomy: Clinical features,
risk factors, and management outcomes. Asia Pac J Ophthalmol
(Phila). 5:192–195. 2016.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Ibarra MS, Hermel M, Prenner JL and Hassan
TS: Longer-term outcomes of transconjunctival sutureless 25-gauge
vitrectomy. Am J Ophthalmol. 139:831–836. 2005.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Hsu J, Chen E, Gupta O, Fineman MS, Garg
SJ and Regillo CD: Hypotony after 25-gauge vitrectomy using oblique
versus direct cannula insertions in fluid-filled eyes. Retina.
28:937–940. 2008.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Zhao LQ, Zhu H, Zhao PQ and Hu YQ: A
systematic review and meta-analysis of clinical outcomes of
vitrectomy with or without intravitreal bevacizumab pretreatment
for severe diabetic retinopathy. Br J Ophthalmol. 95:1216–1222.
2011.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Qu J, Chen X, Liu Q, Wang F, Li M, Zhou Q,
Yao J and Li X: Prophylactic intravitreal injection of aflibercept
for preventing postvitrectomy hemorrhage in proliferative diabetic
retinopathy: A randomized controlled trial. Front Public Health.
10(1067670)2023.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Bahr TA and Bakri SJ: Update on the
management of diabetic retinopathy: Anti-VEGF agents for the
prevention of complications and progression of nonproliferative and
proliferative retinopathy. Life (Basel). 13(1098)2023.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Kaiser SM, Arepalli S and Ehlers JP:
Current and future anti-VEGF agents for neovascular age-related
macular degeneration. J Exp Pharmacol. 13:905–912. 2021.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Chang E, Josan AS, Purohit R, Patel CK and
Xue K: A network meta-analysis of retreatment rates following
bevacizumab, ranibizumab, aflibercept, and laser for retinopathy of
prematurity. Ophthalmology. 129:1389–1401. 2022.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Li X, Xu G, Wang Y, Xu X, Liu X, Tang S,
Zhang F, Zhang J, Tang L, Wu Q, et al: Safety and efficacy of
conbercept in neovascular age-related macular degeneration: results
from a 12-month randomized phase 2 study: AURORA study.
Ophthalmology. 121:1740–1747. 2014.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Wang Q, Li T, Wu Z, Wu Q, Ke X, Luo D and
Wang H: Novel VEGF decoy receptor fusion protein conbercept
targeting multiple VEGF isoforms provide remarkable
anti-angiogenesis effect in vivo. PLoS One.
8(e70544)2013.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Ferrara N: Role of vascular endothelial
growth factor in physiologic and pathologic angiogenesis:
Therapeutic implications. Semin Oncol. 29 (6 Suppl 16):S10–S14.
2002.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Su L, Ren X, Wei H, Zhao L, Zhang X, Liu
J, Su C, Tan L and Li X: INTRAVITREAL conbercept (KH902) for
surgical treatment of severe proliferative diabetic retinopathy.
Retina. 36:938–943. 2016.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Farahvash MS, Majidi AR, Roohipoor R and
Ghassemi F: Preoperative injection of intravitreal bevacizumab in
dense diabetic vitreous hemorrhage. Retina. 31:1254–1260.
2011.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Modarres M, Nazari H, Falavarjani KG,
Naseripour M, Hashemi M and Parvaresh MM: Intravitreal injection of
bevacizumab before vitrectomy for proliferative diabetic
retinopathy. Eur J Ophthalmol. 19:848–852. 2009.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Li H, Niu Y, Rong A, Bi Y, Xu W and Cui H:
Effect of adjunctive intravitreal conbercept injection at the end
of 25G vitrectomy on severe proliferative diabetic retinopathy:
6-month outcomes of a randomised controlled trial. Ophthalmol Ther.
12:1173–1180. 2023.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Someya H, Takayama K, Takeuchi M, Yokoyama
H, Kimura T, Morioka M, Takamura Y, Sameshima S, Ueda T, Ogata N,
et al: Outcomes of 25-gauge vitrectomy for tractional and
nontractional diabetic macular edema with proliferative diabetic
retinopathy. J Ophthalmol. 2019(5304524)2019.PubMed/NCBI View Article : Google Scholar
|
